A Multiple Dose Human Tolerability and Pharmacokinetic Study of IBI362 in Chinese Patients With Type 2 Diabetes Mellitus and Poor Glycemic Control
Latest Information Update: 05 Jul 2022
At a glance
- Drugs Mazdutide (Primary) ; Dulaglutide
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Innovent Biologics
- 28 Jun 2022 According to an Innovent Biologics media release, Professor Wenying Yang of China-Japan Friendship Hospital, is the primary investigator of the study
- 28 Jun 2022 According to an Innovent Biologics media release, results of this study have been published in Nature Communications1
- 28 Jun 2022 Results published in the Innovent Biologics Media Release